Results 111 to 120 of about 112,411 (265)

Efficacy of Upadacitinib in a Middle‐Aged Man With Netherton Syndrome Refractory to Dupilumab: A Case Report

open access: yes
The Journal of Dermatology, EarlyView.
Bo‐Jie Yu   +4 more
wiley   +1 more source

Early Risk Assessment and Recognition of Allergies in Children: Rationale, Methodology, and Proposed Algorithms

open access: yesAllergy, EarlyView.
ABSTRACT Background Atopic diseases—including atopic dermatitis (AD), food allergy (FA), allergic rhinitis (AR), and asthma—are the most common chronic conditions in childhood and adolescence, affecting up to 30% of the global population. In Germany alone, more than 2.1 million children and adolescents are affected.
E. Hamelmann   +13 more
wiley   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

open access: yesAllergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter   +20 more
wiley   +1 more source

Childhood eczema [PDF]

open access: yesBMJ, 2005
Miriam, Santer   +2 more
openaire   +2 more sources

Eczema

open access: yesInternational Journal of Clinical Practice, 1953
openaire   +2 more sources

Nail Dystrophy Treated With Marigold Therapy in a Patient With Epidermolysis Bullosa Simplex

open access: yes
Australasian Journal of Dermatology, EarlyView.
Aalia Syed   +2 more
wiley   +1 more source

Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema

open access: yesAllergy, EarlyView.
This study performed an unbiased molecular profiling of CHE patients across diverse etiologies to identify shared pathogenic drivers and evaluate the impact of IL‐4Rα blockade via dupilumab over 16 weeks. CHE shows a mixed immune signature involving type 1, 2, and 3 pathways with features of atopic dermatitis and psoriasis.
Perrine Gery   +25 more
wiley   +1 more source

Home - About - Disclaimer - Privacy